# Run review: `retinopathy-arabic-sources-20261102-1`

**Run date:** 2 November 2026. **Reviewed:** 3 November 2026. **Model:** local `qwen3:8b`.

The first drill using the expanded Arabic/English UAE source pack completed with 32 decisions, two evidence-limited governance assessments, and a verified hash chain. The synthetic Dubai clinic operator recommended a halt pending human approval at step 7, which triggered a step 8 request to review manual screening capacity and patient follow-up. No real service was halted and no external message or regulatory action was sent.

The active clinic role is now correctly labeled `dubai_clinic_operator`; EHS is retained only in historical run artifacts. The run retrieved the new Arabic EDE pharmacovigilance guideline and English medical-products law, but retrieval did not establish the fictional product's UAE classification, marketing authorization, Article 68 report status, or Article 70 case status. Those facts remained explicitly unverified.

## Evidence review

The audit initially found 13 decisions with no recorded citation. Manual passage review then identified four additional weak citations:

- `log-2-ede` cited Article 68 reporting categories, not the invoked Article 68(7) or Article 70(2) information-request authority.
- `log-6-ede` cited a PDPL cross-border-transfer passage that does not establish EDE manufacturer-evidence powers.
- `log-7-ede` cited a marketing-approval cancellation passage rather than an applicable evidence-request provision.
- `log-8-dubai_clinic_operator` cited general WHO transparency and testing guidance, which does not establish manual screening capacity or patient follow-up for the clinic.

These cases are recorded as `CR-020` through `CR-023` in `data/claim_review_seed.csv`, all as `UNSUPPORTED`. Action-specific screening now requires manufacturer-information or investigation language for `request_ede_manufacturer_evidence`, and manual-capacity, human-review, or patient-follow-up language for `request_manual_review`. English and Arabic patterns are included. Retrospective audit now reports the 13 no-citation decisions plus all four citation-review findings.

`make evaluate-claims` now covers 23 deliberately selected cases. Manual labels are 20 `UNSUPPORTED`, one `INSUFFICIENT_EVIDENCE`, and two `PARTIALLY_SUPPORTED`; triage outputs are 19, three, and one respectively. This issue-focused seed is not a general accuracy estimate. The remaining disagreement includes one conservative false warning and two no-citation cases whose manual label is unsupported.

## Verification and limitations

`make verify-log RUN=retinopathy-arabic-sources-20261102-1` verifies the 32-entry chain ending at `082ebc7f161d99061a9af76a00c0f154c25342315bab06f217e72015c4982889`. `make audit-evidence RUN=retinopathy-arabic-sources-20261102-1` reports 17 findings: 13 no-citation decisions and four citations requiring review. The audit is lexical and metadata triage only. Arabic OCR, translations, exact statutory meaning, product classification, incident applicability, institutional powers, and the validity of all other citations still require qualified human review.
